Literature DB >> 18365831

Osteoclasts - the innate immune cells of the bone.

Yalei Wu1, Mary Beth Humphrey, Mary C Nakamura.   

Abstract

Osteopenia and periarticular bony erosion are consequences of chronic inflammatory autoimmune disease due to an imbalance of osteoclast activity relative to new bone formation. Osteoclasts, which are specialized as the only bone resorbing cell type, are differentiated from hematopoietic myeloid precursor cells. Inflammatory signals mediated by multiple types of immune cells and cytokines have significant influence over osteoclast differentiation and function through direct effects on osteoclast precursors and indirect effects via osteoblasts and other cells in the bony microenvironment including synovial cells, stromal cells, osteocytes and chondrocytes. Recent studies have demonstrated that osteoclasts themselves express a number of immune receptors and are regulated similarly to macrophages and dendritic cells, closely related cells in the innate immune system. Though we are only beginning to understand the roles of innate immune receptors in osteoclasts, some of these receptors have been shown to be critical regulators of differentiation and function of osteoclasts. Osteoclasts likely function as the innate immune cells of the bone, thus are highly regulated to appropriately respond to stress and inflammatory changes in their microenvironment.

Entities:  

Mesh:

Year:  2008        PMID: 18365831     DOI: 10.1080/08916930701693180

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  21 in total

1.  TREM2 and β-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis.

Authors:  Karel Otero; Masahiro Shinohara; Haibo Zhao; Marina Cella; Susan Gilfillan; Angela Colucci; Roberta Faccio; F Patrick Ross; Steve L Teitelbaum; Hiroshi Takayanagi; Marco Colonna
Journal:  J Immunol       Date:  2012-02-06       Impact factor: 5.422

Review 2.  Mediators of the inflammatory response to joint replacement devices.

Authors:  Neil Cobelli; Brian Scharf; Giovanna M Crisi; John Hardin; Laura Santambrogio
Journal:  Nat Rev Rheumatol       Date:  2011-09-06       Impact factor: 20.543

Review 3.  Epigenetics and Bone Remodeling.

Authors:  Ali Husain; Matlock A Jeffries
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

4.  Type 1 interferons suppress accelerated osteoclastogenesis and prevent loss of bone mass during systemic inflammatory responses to Pneumocystis lung infection.

Authors:  Michelle Wilkison; Katherine Gauss; Yanchao Ran; Steve Searles; David Taylor; Nicole Meissner
Journal:  Am J Pathol       Date:  2012-05-22       Impact factor: 4.307

Review 5.  Bone and the innate immune system.

Authors:  Julia F Charles; Mary C Nakamura
Journal:  Curr Osteoporos Rep       Date:  2014-03       Impact factor: 5.096

6.  Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.

Authors:  Gang An; Chirag Acharya; Xiaoyan Feng; Kenneth Wen; Mike Zhong; Li Zhang; Nikhil C Munshi; Lugui Qiu; Yu-Tzu Tai; Kenneth C Anderson
Journal:  Blood       Date:  2016-07-14       Impact factor: 22.113

7.  C1 Silencing Attenuates Inflammation and Alveolar Bone Resorption in Endodontic Disease.

Authors:  Yuhui Wang; Wei Chen; Liang Hao; Abigail McVicar; Jinjin Wu; Ning Gao; Yuehua Liu; Yi-Ping Li
Journal:  J Endod       Date:  2019-05-16       Impact factor: 4.171

8.  A Statistical Framework for Pathway and Gene Identification from Integrative Analysis.

Authors:  Quefeng Li; Menggang Yu; Sijian Wang
Journal:  J Multivar Anal       Date:  2017-01-21       Impact factor: 1.473

9.  Silencing of Ac45 Simultaneously Inhibits Osteoclast-Mediated Bone Resorption and Attenuates Dendritic Cell-Mediated Inflammation through Impairing Acidification and Cathepsin K Secretion.

Authors:  Wenbin Yang; Zheng Zhu; Longjiang Li; Abigail McVicar; Ning Gao; Lin Wang; Yi-Ping Li; Wei Chen
Journal:  Infect Immun       Date:  2020-12-15       Impact factor: 3.441

Review 10.  Myeloma and Bone Disease.

Authors:  Cristina Panaroni; Andrew J Yee; Noopur S Raje
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.